3 Small-Caps That Might Be Acquisition Candidates

A lot of small biotechs are fantastic buys right now. With Big Pharma sitting on a lot of cash, we might start seeing some smart acquisitions later this year.

We asked a trio of contributors to pick the biotechs they're feeling most bullish about as potential buyout candidates in 2022. Their choices: OptimizeRx (NASDAQ: OPRX), Affimed (NASDAQ: AFMD), and Blueprint Medicines (NASDAQ: BPMC).

Image source: Getty Images.

Continue reading

Source Fool.com